DK3209302T3 - Carbidopa og l-dopa prodrugs og deres anvendelse til behandling af parkinsons sygdom - Google Patents

Carbidopa og l-dopa prodrugs og deres anvendelse til behandling af parkinsons sygdom Download PDF

Info

Publication number
DK3209302T3
DK3209302T3 DK15791424.3T DK15791424T DK3209302T3 DK 3209302 T3 DK3209302 T3 DK 3209302T3 DK 15791424 T DK15791424 T DK 15791424T DK 3209302 T3 DK3209302 T3 DK 3209302T3
Authority
DK
Denmark
Prior art keywords
carbidopa
dopa
parkinson
disease
products
Prior art date
Application number
DK15791424.3T
Other languages
Danish (da)
English (en)
Inventor
Benoit Cardinal-David
Kassibla E Dempah
Brian P Enright
Ye Huang
Russell C Klix
Scott W Krabbe
Philip R Kym
Yanbin Lao
Xiaochun Lou
Sean E Mackey
Mark A Matulenko
Peter T Mayer
Christopher P Miller
James Stambuli
Eric A Voight
Zhi Wang
Geoff G Zhang
Valentino J Stella
Vincent S Chan
Rodger F Henry
Raimundo Ho
Alexander D Huters
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3209302(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Application granted granted Critical
Publication of DK3209302T3 publication Critical patent/DK3209302T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK15791424.3T 2014-10-21 2015-10-21 Carbidopa og l-dopa prodrugs og deres anvendelse til behandling af parkinsons sygdom DK3209302T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462066771P 2014-10-21 2014-10-21
PCT/US2015/056686 WO2016065019A1 (en) 2014-10-21 2015-10-21 Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease

Publications (1)

Publication Number Publication Date
DK3209302T3 true DK3209302T3 (da) 2019-05-13

Family

ID=54478240

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15791424.3T DK3209302T3 (da) 2014-10-21 2015-10-21 Carbidopa og l-dopa prodrugs og deres anvendelse til behandling af parkinsons sygdom

Country Status (37)

Country Link
US (7) US9446059B2 (OSRAM)
EP (3) EP3569587A1 (OSRAM)
JP (6) JP6567049B2 (OSRAM)
KR (3) KR20240113982A (OSRAM)
CN (4) CN111362980B (OSRAM)
AR (1) AR102389A1 (OSRAM)
AU (4) AU2015335941B2 (OSRAM)
BR (1) BR112017008198B1 (OSRAM)
CA (1) CA2965379A1 (OSRAM)
CY (2) CY1121826T1 (OSRAM)
DK (1) DK3209302T3 (OSRAM)
ES (1) ES2739536T3 (OSRAM)
FI (1) FIC20230014I1 (OSRAM)
FR (1) FR23C1035I2 (OSRAM)
HR (1) HRP20191285T1 (OSRAM)
HU (2) HUE044115T2 (OSRAM)
IL (3) IL251829B (OSRAM)
LT (2) LT3209302T (OSRAM)
LU (1) LUC00304I2 (OSRAM)
MX (2) MX381069B (OSRAM)
MY (1) MY189519A (OSRAM)
NL (1) NL301224I2 (OSRAM)
NO (1) NO2023013I1 (OSRAM)
PH (1) PH12017500746B1 (OSRAM)
PL (1) PL3209302T3 (OSRAM)
PT (1) PT3209302T (OSRAM)
RS (1) RS58972B1 (OSRAM)
RU (2) RU2743347C2 (OSRAM)
SA (1) SA521421115B1 (OSRAM)
SG (1) SG11201703170RA (OSRAM)
SI (1) SI3209302T1 (OSRAM)
SM (1) SMT201900376T1 (OSRAM)
TR (1) TR201908296T4 (OSRAM)
TW (2) TWI718999B (OSRAM)
UA (1) UA120437C2 (OSRAM)
WO (1) WO2016065019A1 (OSRAM)
ZA (1) ZA201702760B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
HRP20201948T1 (hr) 2014-03-13 2021-01-22 Neuroderm Ltd Pripravci inhibitora dopa-dekarbokilaze
KR20240113982A (ko) 2014-10-21 2024-07-23 애브비 인코포레이티드 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도
JP2019515908A (ja) * 2016-04-20 2019-06-13 アッヴィ・インコーポレイテッド カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
US11148999B2 (en) 2016-06-22 2021-10-19 MedChem Partners, LLC Nitric oxide donors
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US20180311238A1 (en) * 2017-04-28 2018-11-01 Saniona A/S Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
PE20211290A1 (es) 2017-11-24 2021-07-20 H Lundbeck As Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad del parkinson
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
EP3849533A4 (en) 2018-09-13 2022-06-22 University of Canberra Methods of inhibition
TW202031265A (zh) 2018-11-15 2020-09-01 美商艾伯維有限公司 用於皮下投藥之醫藥調配物
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
JP7641234B2 (ja) 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2020234276A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
US12398106B2 (en) 2019-05-21 2025-08-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson's disease
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
DD230865B1 (de) * 1982-08-09 1987-05-20 Dresden Arzneimittel Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
US4616484A (en) 1984-11-30 1986-10-14 Kysor Industrial Corporation Vehicle refrigerant heating and cooling system
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
EP0393781B1 (en) * 1989-04-20 1995-02-08 ZAMBON GROUP S.p.A. Dopamine pro-drug
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
CA2309792A1 (en) * 1997-11-12 1999-05-20 William C. Shakespeare Novel signal transduction inhibitors, compositions containing them
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
WO2004000863A1 (ja) 2002-06-20 2003-12-31 Nippon Suisan Kaisha, Ltd. プロドラッグ、その医薬としての使用、およびその製法
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
WO2004069146A2 (en) 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
CN1845728B (zh) * 2003-08-29 2013-06-19 转化医药公司 包含左旋多巴和卡比多巴的药物组合物
ATE495739T1 (de) 2003-08-29 2011-02-15 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
CA2543181A1 (en) 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
CN101023056B (zh) 2004-06-04 2011-05-25 克塞诺波特公司 左旋多巴前药、和组合物及其应用
AU2005270124B2 (en) 2004-07-06 2011-09-08 Abbvie Inc. Prodrugs of HIV protease inhibitors
WO2007067495A2 (en) * 2005-12-05 2007-06-14 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
RU2484815C2 (ru) * 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
AU2007259256A1 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and L-DOPA
WO2008076458A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
NZ587168A (en) * 2008-02-06 2011-06-30 Wockhardt Research Center Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
BRPI0912326A2 (pt) 2008-05-20 2015-10-06 Neurogesx Inc análogos de acetaminofeno hidrossolúveis
DK3192500T3 (da) 2009-05-19 2020-12-21 Neuroderm Ltd Sammensætninger til kontinuerlig indgivelse af dopa-decarboxylasehæmmere
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
ES2565644T3 (es) 2009-11-09 2016-04-06 Xenoport, Inc. Composiciones farmacéuticas y formas de dosificación oral de un pre medicamento de levodopa y los métodos de utilización
WO2011109767A2 (en) 2010-03-04 2011-09-09 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
EP3326615B1 (en) 2010-11-15 2020-01-08 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
BR112013013551A2 (pt) 2010-12-02 2016-10-11 Ono Pharmaceutical Co composto e uso médico do mesmo
US20140088192A1 (en) 2010-12-10 2014-03-27 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
WO2012158527A2 (en) * 2011-05-13 2012-11-22 Howmedica Osteonics Organophosphorous & multivalent metal compound compositions & methods
KR20130070371A (ko) * 2011-12-19 2013-06-27 울산대학교 산학협력단 퇴행성 신경질환 예방 또는 치료용 조성물
AU2014229127B2 (en) 2013-03-13 2018-04-05 Neuroderm Ltd Method for treatment of parkinson's disease
CA2917145C (en) 2013-03-15 2023-10-24 Techfields Pharma Co., Ltd. Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases
KR20240113982A (ko) * 2014-10-21 2024-07-23 애브비 인코포레이티드 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
JP2019515908A (ja) 2016-04-20 2019-06-13 アッヴィ・インコーポレイテッド カルビドパ及びｌ−ドパプロドラッグ並びに使用方法
EP3518920A1 (en) 2016-09-29 2019-08-07 Berlirem GmbH L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
JP2021183628A (ja) 2021-12-02
MY189519A (en) 2022-02-16
US11091507B2 (en) 2021-08-17
IL268885B (en) 2020-08-31
JP6567049B2 (ja) 2019-08-28
BR112017008198A2 (pt) 2017-12-26
FR23C1035I1 (fr) 2023-12-08
PT3209302T (pt) 2019-07-19
IL276493A (en) 2020-09-30
TW201630924A (zh) 2016-09-01
AU2025238004A1 (en) 2025-10-16
RU2017117413A3 (OSRAM) 2019-05-30
CY2023010I1 (el) 2023-06-09
HUE044115T2 (hu) 2019-10-28
KR20170071599A (ko) 2017-06-23
FIC20230014I1 (fi) 2023-03-31
CN111454290A (zh) 2020-07-28
CN111362980A (zh) 2020-07-03
NZ769153A (en) 2024-04-26
CN111362980B (zh) 2022-10-18
JP6932227B2 (ja) 2021-09-08
KR20230066484A (ko) 2023-05-15
TWI755257B (zh) 2022-02-11
SA521421115B1 (ar) 2022-03-01
FR23C1035I2 (fr) 2025-04-18
CN111494395B (zh) 2024-06-21
IL251829A0 (en) 2017-06-29
LUC00304I2 (OSRAM) 2025-09-22
EP4186510A1 (en) 2023-05-31
JP2023174770A (ja) 2023-12-08
LT3209302T (lt) 2019-06-10
CN111494395A (zh) 2020-08-07
MX381069B (es) 2025-03-12
UA120437C2 (uk) 2019-12-10
SI3209302T1 (sl) 2019-06-28
CA2965379A1 (en) 2016-04-28
PL3209302T3 (pl) 2019-10-31
MX2021003840A (es) 2022-06-30
US20160106765A1 (en) 2016-04-21
TR201908296T4 (tr) 2019-06-21
JP7688087B2 (ja) 2025-06-03
JP6750076B2 (ja) 2020-09-02
SMT201900376T1 (it) 2019-09-09
PH12017500746A1 (en) 2017-10-30
CY1121826T1 (el) 2020-07-31
NO2023013I1 (no) 2023-03-20
AR102389A1 (es) 2017-02-22
KR102537018B1 (ko) 2023-05-30
PH12017500746B1 (en) 2021-12-15
NZ730996A (en) 2024-04-26
JP2017537066A (ja) 2017-12-14
EP3209302B1 (en) 2019-04-24
MX393568B (es) 2025-03-24
LTPA2023519I1 (OSRAM) 2023-06-26
IL251829B (en) 2019-09-26
NL301224I2 (nl) 2023-08-16
US20220153765A1 (en) 2022-05-19
JP2025118978A (ja) 2025-08-13
EP3209302A1 (en) 2017-08-30
NL301224I1 (OSRAM) 2023-03-29
WO2016065019A1 (en) 2016-04-28
HRP20191285T1 (hr) 2019-10-18
US20200262852A1 (en) 2020-08-20
US10174061B2 (en) 2019-01-08
HUS2300009I1 (hu) 2023-03-28
US10730895B2 (en) 2020-08-04
MX2017005236A (es) 2017-07-26
US20160362431A1 (en) 2016-12-15
AU2015335941B2 (en) 2021-04-01
CN107206013A (zh) 2017-09-26
KR20240113982A (ko) 2024-07-23
RU2021103000A (ru) 2021-03-01
BR112017008198B1 (pt) 2021-02-09
ES2739536T3 (es) 2020-01-31
US20180079762A1 (en) 2018-03-22
AU2021201414A1 (en) 2021-03-25
RU2017117413A (ru) 2018-11-26
AU2023210650A1 (en) 2023-08-24
ZA201702760B (en) 2022-05-25
US9446059B2 (en) 2016-09-20
CY2023010I2 (el) 2023-06-09
IL268885A (en) 2019-10-31
RS58972B1 (sr) 2019-08-30
US20190375770A1 (en) 2019-12-12
SG11201703170RA (en) 2017-05-30
TWI718999B (zh) 2021-02-21
EP3569587A1 (en) 2019-11-20
LTC3209302I2 (OSRAM) 2025-10-10
AU2021201414B2 (en) 2023-05-11
RU2743347C2 (ru) 2021-02-17
TW202131931A (zh) 2021-09-01
CN111454290B (zh) 2022-12-23
JP2019218356A (ja) 2019-12-26
AU2015335941A1 (en) 2017-05-04
US20230106081A1 (en) 2023-04-06
JP2020189864A (ja) 2020-11-26

Similar Documents

Publication Publication Date Title
DK3209302T3 (da) Carbidopa og l-dopa prodrugs og deres anvendelse til behandling af parkinsons sygdom
DK3789501T3 (da) Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom
DK3364997T3 (da) Aspartoacylase genterapi til behandling af canavans sygdom
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3204497T3 (da) Terapeutisk hæmning af lactatdehydrogenase og midler dertil
DK2968218T3 (da) Kombination til behandling af parkinsons sygdom
ZA201703507B (en) Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof
DK3233066T3 (da) Orlistat- og acarbosepræparat med modificeret frigivelse til behand-ling af obesitas og relaterede metaboliske lidelser
DK3142664T3 (da) Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
LT3463351T (lt) Parkinsono ligos gydymas
DK3722291T3 (da) Indolinonforbindelser og deres anvendelse i behandlingen af fibrotiske sygdomme
EP3487986A4 (en) METHOD FOR THE MICROBIAL PRODUCTION OF SPECIFIC NATURAL CAPSAICINOIDS
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
DK3169405T3 (da) Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme
DK3442558T3 (da) Bmp-7-afledte peptider til anvendelse i behandlingen af osteoartritis
DK3458045T3 (da) Ebselen til anvendelse i behandling af menieres sygdom
DK3229811T3 (da) Forebyggelse og behandling af betændelseslidelser
ITUA20162283A1 (it) Tonometro indossabile perfezionato
DK3137094T3 (da) Behandling og forebyggelse af alzheimers sygdom (ad)
DK3182980T3 (da) Behandling af glykosyleringsmangelsygdomme
DK3364975T3 (da) Kombination af trazodon og gabapentin til behandling af smerter
PL3148588T3 (pl) N,n-bis-2-merkaptoetyloizoftalamid do leczenia choroby parkinsona
DK3200785T3 (da) Behandling af paroxysmal ekstrem smertelidelse
DK3294288T3 (da) Inhibitorer af replikation af humant papillomavirus